Bank Of America Corp Clovis Oncology, Inc. Transaction History

Bank Of America Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $1,119 - $3,038	1,066 Added 10.78%	10,958 $13,000
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $27,989 - $131,503	-44,427 Reduced 81.79%	9,892 $17,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $2.1 Million - $4.61 Million	-1,468,482 Reduced 96.43%	54,319 $110,000
Q4 2021 Feb 08, 2022	BUY	$2.7 - $4.76 $3.91 Million - $6.89 Million	1,447,711 Added 1927.97%	1,522,801 $4.13 Million
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $98,122 - $140,174	-24,168 Reduced 24.35%	75,090 $335,000
Q2 2021 Sep 13, 2021	BUY	$5.02 - $7.05 $498,275 - $699,768	99,258 New	99,258 $576,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.